CCCC C4 Therapeutics

C4 Therapeutics to Participate in Upcoming September Investor Conferences

C4 Therapeutics to Participate in Upcoming September Investor Conferences

WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in fireside chats at two September investor conferences.

Fireside Chat Details:

Event: Wells Fargo Healthcare Conference taking place in Boston, MA

Date/Time: September 5, 2024 at 8:45 AM ET

Event: 2024 Cantor Global Healthcare Conference taking place in New York, New York

Date/Time: September 18, 2024 at 8:35 AM ET

Live webcasts will be available on the Investors section of the company’s website at . Archived replays of the webcasts will be available for approximately 30 days following the live events.

About C4 Therapeutics

C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit .

Contacts:

Investors:

Courtney Solberg

Senior Manager, Investor Relations

Media:

Loraine Spreen

Senior Director, Corporate Communications & Patient Advocacy



EN
29/08/2024

Underlying

CCCCC4 Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on C4 Therapeutics

 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5...

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WATERTOWN, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 146,880 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the gr...

September 30, 2024 1 EN
 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mecha...

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 CFT1946 Is Well-Tolerated at All Dose Levels; No Dose-Limiting Toxicities CFT1946 Achieves Dose Proportional Pharmacokinetic Exposure; Successfully Degrades BRAF V600 Mutant Protein Early Evidence of CFT1946 Monotherapy Anti-Tumor Activity in Patients Who Have Progressed on or After BRAF Inhibitor Therapies; Majority of Patients ...

September 13, 2024 1 EN
 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics Announces Delivery of Second Development Candidate to ...

C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen Milestone Results in $8 Million Payment to C4 Therapeutics WATERTOWN, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced it has successfully delivered a second development candidate to Biogen and earned an $8 million milestone payment. This marks the final development candidate under this strategic collaboration. “We are thrilled to deliver a highly catalytic...

September 10, 2024 1 EN
 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Cli...

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024 Abstract Released Today Highlights Favorable Safety Profile and Early Evidence of Monotherapy Anti-Tumor Activity Investor Webcast to be Held Friday, September 13, 2024 at 12:00 pm ET WATERTOWN, Mass., Sept. 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the abstract sharing clinical data fr...

September 8, 2024 1 EN
 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, ...

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Stephen (Steve) Fawell, Ph.D. as a director. With this appointment, Malcolm Salter has decided to retire from the Board of Directors after nearly a decade of service. “We are excited to welcome Steve to th...

September 3, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch